Skip to main content

Innovation Pharmaceuticals Stock Forecast, Price & News

0.00 (0.00 %)
(As of 05/14/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume705,298 shs
Average Volume2.17 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive IPIX News and Ratings via Email

Sign-up to receive the latest news and ratings for Innovation Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Innovation Pharmaceuticals logo

About Innovation Pharmaceuticals

Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. It develops Brilacidin, a lead drug compound for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company also develops Kevetrin, a lead anti-cancer compound for treating ovarian cancer. It has license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts.


Innovation Pharmaceuticals (OTCMKTS:IPIX) Trading Down 3.3%
Innovation Pharmaceuticals (OTCMKTS:IPIX) Trading Down 3.3%
April 28, 2021 |
See More Headlines

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolOTCMKTS:IPIX
Phone(978) 236-8717
Year FoundedN/A

Sales & Book Value

Annual SalesN/A





Next Earnings DateN/A
OptionableNot Optionable


Overall MarketRank

0.56 out of 5 stars

Medical Sector

1458th out of 2,044 stocks

Biotechnology Industry

76th out of 158 stocks

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Innovation Pharmaceuticals (OTCMKTS:IPIX) Frequently Asked Questions

What stocks does MarketBeat like better than Innovation Pharmaceuticals?

Wall Street analysts have given Innovation Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Innovation Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Innovation Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Innovation Pharmaceuticals' stock was trading at $0.1250 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IPIX stock has increased by 49.3% and is now trading at $0.1866.
View which stocks have been most impacted by COVID-19

Who are Innovation Pharmaceuticals' key executives?

Innovation Pharmaceuticals' management team includes the following people:
  • Mr. Leo Ehrlich, Chairman, CEO, CFO, Principal Accounting Officer & Sec. (Age 63, Pay $465.85k)
  • Ms. Jane Harness, Sr. VP of Clinical Sciences & Portfolio Management (Age 53, Pay $365.75k)
  • Dr. W. James Alexander, Consultant (Age 71)
  • Mr. Jim Boeheim, Bus. Advisor

Who are some of Innovation Pharmaceuticals' key competitors?

What other stocks do shareholders of Innovation Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovation Pharmaceuticals investors own include Vaxart (VXRT), Broadcom (AVGO), Fulcrum Therapeutics (FULC), VIVUS (VVUS), CytoDyn (CYDY), ServiceNow (NOW), Sorrento Therapeutics (SRNE), United Airlines (UAL), Heat Biologics (HTBX) and Micron Technology (MU).

What is Innovation Pharmaceuticals' stock symbol?

Innovation Pharmaceuticals trades on the OTCMKTS under the ticker symbol "IPIX."

How do I buy shares of Innovation Pharmaceuticals?

Shares of IPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Innovation Pharmaceuticals' stock price today?

One share of IPIX stock can currently be purchased for approximately $0.19.

How many employees does Innovation Pharmaceuticals have?

Innovation Pharmaceuticals employs 4 workers across the globe.

What is Innovation Pharmaceuticals' official website?

The official website for Innovation Pharmaceuticals is

Where are Innovation Pharmaceuticals' headquarters?

Innovation Pharmaceuticals is headquartered at 100 Cummings Ctr Ste 151b, BEVERLY, MA 01915-6117, United States.

How can I contact Innovation Pharmaceuticals?

Innovation Pharmaceuticals' mailing address is 100 Cummings Ctr Ste 151b, BEVERLY, MA 01915-6117, United States. The company can be reached via phone at (978) 236-8717.

This page was last updated on 5/15/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.